Cargando…

Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways

Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Xiangping, North, Brian J., Inuzuka, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102811/
https://www.ncbi.nlm.nih.gov/pubmed/24912918
_version_ 1782327069809573888
author Dai, Xiangping
North, Brian J.
Inuzuka, Hiroyuki
author_facet Dai, Xiangping
North, Brian J.
Inuzuka, Hiroyuki
author_sort Dai, Xiangping
collection PubMed
description Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumors through the action of the histone methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a variety of tumors, it remains unclear if other mechanisms contribute to functional inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally down-regulated by two independent mechanisms. First, we identified that Akt1 can phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be degraded in part through ubiquitin-proteasome pathway by SCF(Fbw7). DAB2IP harbors two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1δ. Our data hence indicate that in addition to epigenetic down-regulation, two additional pathways can functional inactivate DAB2IP. Given that DAB2IP has previously been identified to possess direct causal role in tumorigenesis and metastasis, our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development, and therefore highlight DAB2IP agonists as potential therapeutic approaches for future anti-cancer drug development.
format Online
Article
Text
id pubmed-4102811
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-41028112014-07-23 Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways Dai, Xiangping North, Brian J. Inuzuka, Hiroyuki Oncotarget Research Paper Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumors through the action of the histone methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a variety of tumors, it remains unclear if other mechanisms contribute to functional inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally down-regulated by two independent mechanisms. First, we identified that Akt1 can phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be degraded in part through ubiquitin-proteasome pathway by SCF(Fbw7). DAB2IP harbors two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1δ. Our data hence indicate that in addition to epigenetic down-regulation, two additional pathways can functional inactivate DAB2IP. Given that DAB2IP has previously been identified to possess direct causal role in tumorigenesis and metastasis, our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development, and therefore highlight DAB2IP agonists as potential therapeutic approaches for future anti-cancer drug development. Impact Journals LLC 2014-05-01 /pmc/articles/PMC4102811/ /pubmed/24912918 Text en Copyright: © 2014 Dai et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Dai, Xiangping
North, Brian J.
Inuzuka, Hiroyuki
Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
title Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
title_full Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
title_fullStr Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
title_full_unstemmed Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
title_short Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
title_sort negative regulation of dab2ip by akt and scf(fbw7) pathways
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102811/
https://www.ncbi.nlm.nih.gov/pubmed/24912918
work_keys_str_mv AT daixiangping negativeregulationofdab2ipbyaktandscffbw7pathways
AT northbrianj negativeregulationofdab2ipbyaktandscffbw7pathways
AT inuzukahiroyuki negativeregulationofdab2ipbyaktandscffbw7pathways